Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Compendia: Research Models: Tau Mutations
PP2A Cα mutant L309A

Posted 3 August 2010

General Information

Transgene: A 978bp cDNA of human PP2A C was fused to haemagglutinin (HA) epitope. The L309A mutant introduced into cDNA. Neuron-specific mThy1.2 vector. Mice express dominant negative mutant form.

Mutation: L309A

Promoter: Murine Thy1.2

Mouse strain: B6D2F1×B6D2F1. Background C57BL/6.

Phenotype

Neuropathological Analysis:

Strong expression of transgene in hippocampus and cortex. No neurological impairment or neurodegeneration. Transgene expressed in brain areas affected by tau pathology and neurodegeneration in AD.

When crossed with P301L (pR5) mice bigenic mice show 7-fold increase numbers of hippocampal neurons that phosphorylate the pathological S422 epitope of tau. Also 8-fold increase numbers of tangles compared to pR5 mice.

Behavioral:

Normal size and fertility. No behavioral problems. Unaffected motor function on rotarod. Delayed postnatal development and hypoplasia of the Harderian gland, causing slit-eye phenotype (enophthalmos).

Availability

Lars Ittner or Jürgen Götz
Alzheimer’s and Parkinson’s Disease Lab, Brain and Mind Res. Institute
University of Sydney, Camperdown,, NSW 2050, Australia
Phone: +61-2-9351 0789 (or 0799)
Fax: +61-2-9351-0731
E-mail: Jürgen Götz (juergen.goetz@sydney.edu.au) and Lars Ittner (lars.ittner@sydney.edu.au)

Patents: None

References

Primary:

Schild A, Isenmann S , Tanimoto N, Tonagel F, Seeliger MW, Ittner LM, Kretz A, Ogris E, Götz J. Impaired development of the Harderian gland in mutant protein phosphatase 2A transgenic mice. Mech Dev. 2006 May;123(5):362-71. Abstract

Associated:

van Eersel, J, Ke YD, Liu X, Kril J, Götz J, Ittner LM (2010) Sodium selenate treatment mitigates tau pathology in Alzheimer’s disease models, Proc Natl Acad Sci U S A. 2010 Jul 19. Abstract

Deters N, Ittner LM, Götz J. Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochem Biophys Res Commun. 2009 Feb 6;379(2):400-5. Abstract

Schild A, Ittner L, Gotz J. Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice. Biochemical and Biophysical Res. Communications 343, 1171-1178, 2006. Abstract

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark

See recent updates
Alzheimer's Disease Mouse Model Resource
Considerations for Choosing Controls
Research Tools

Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad